Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.79 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.79 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.79 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.79 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.79 |
| ▸ | USP2 | O75604 | 1/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.79 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.79 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.79 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.79 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.79 |
| ▸ | ACE | P12821 | 1/20 | 0.79 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.79 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.79 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.79 |
| ▸ | PDE4A | P27815 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1204559 | 0.99 | PPARG (0.78) | PPARGAGTR1AGTR2KDM4EABCC3 | |
| SCHEMBL1776349 | 0.92 | AGTR1 (0.86) | PPARGAGTR1AGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL4464 | 0.89 | AGTR1 (1.00) | PPARGAGTR1AGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL2122886 | 0.89 | AGTR1 (1.00) | PPARGAGTR1AGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL29691699 | 0.89 | AGTR1 (1.00) | PPARGAGTR1AGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL29356790 | 0.89 | AGTR1 (1.00) | PPARGAGTR1AGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL29414101 | 0.89 | AGTR1 (1.00) | PPARGAGTR1AGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL3936304 | 0.88 | AGTR1 (0.92) | PPARGAGTR1AGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL972356 | 0.88 | AGTR1 (0.98) | PPARGAGTR1AGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL998659 | 0.88 | AGTR1 (0.98) | PPARGAGTR1AGTR2KDM4EABCC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1912975-B1 | A PROCESS FOR THE PREPARATION OF TELMISARTAN | MATRIX LAB LTD (IN) | 2013-01-16 | — | — | EP | disclosed |
| WO-2012028925-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF TELMISARTAN | OGENE SYSTEMS (I) PVT LTD (IN) | 2012-03-08 | — | — | WO | disclosed |
| EP-1587479-B1 | PHARMACEUTICAL COMBINATION FOR THE PROPHYLAXIS OR TREATMENT OF CARDIOVASCULAR, CARDIOPULMONARY, PULMONARY OR RENAL DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2011-12-14 | — | — | EP | disclosed |
| US-20110190277-A1 | PHARMACEUTICAL COMBINATION FOR THE PREVENTION OR TREATMENT OF CARDIOVASCULAR, CARDIOPULMONARY, PULMONARY OR RENAL DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | US | disclosed |
| US-7884214-B2 | Condensing 4-Methyl-2-n-propyl-1H-benzimidazole-6-carboxylic acid with N-Methyl-O-phenylenediamine dihydrochloride to yields 4-methyl-6 (1-methyl benzimidazol-2-yl)-2-n-propyl 1H-benzimidazole, treating intermediate with 4'-(bromomethyl)-2-biphenyl-2-carboxylate in presence of a base, salt formation | MATRIX LABORATORIES LIMITED (IN) | 2011-02-08 | — | — | US | disclosed |
| US-20090023932-A1 | Process for the Preparation of Telmisartan | MATRIX LABORATORIES LTD (IN) | 2009-01-22 | — | — | US | disclosed |
| EP-1818056-A1 | Pharmaceutical combination for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-15 | — | — | EP | disclosed |
| EP-1587584-B1 | PHARMACEUTICAL COMBINATION FOR THE PROPHYLAXIS OR TREATMENT OF CARDIOVASCULAR, CARDIOPULMONARY, PULMONARY OR RENAL DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2007-05-23 | — | — | EP | disclosed |
| US-20060264491-A1 | Telmisartan production process | CHEMAGIS LTD. (IL) | 2006-11-23 | — | — | US | disclosed |
| EP-1587584-A1 | PHARMACEUTICAL COMBINATION FOR THE PROPHYLAXIS OR TREATMENT OF CARDIOVASCULAR, CARDIOPULMONARY, PULMONARY OR RENAL DISEASES | Boehringer Ingelheim International GmbH (DE) | 2005-10-26 | — | — | EP | disclosed |
| EP-1587479-A2 | PHARMACEUTICAL COMBINATION FOR THE PROPHYLAXIS OR TREATMENT OF CARDIOVASCULAR, CARDIOPULMONARY, PULMONARY OR RENAL DISEASES | Boehringer Ingelheim International GmbH (DE) | 2005-10-26 | — | — | EP | disclosed |
| US-20050004193-A1 | Pharmaceutical combination for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary, or renal diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-01-06 | — | — | US | disclosed |
| US-20040259925-A1 | Pharmaceutical compositions and methds for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-12-23 | — | — | US | disclosed |
| WO-2004062557-A2 | PHARMACEUTICAL COMBINATION OF TELMISARTAN AND ATORVASTATIN FOR THE PROPHYLAXIS OR TREATMENT OF CARDIOVASCULAR, CARDIOPULMONARY, PULMONARY OR RENAL DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-07-29 | — | — | WO | disclosed |
| WO-2004062729-A1 | PHARMACEUTICAL COMBINATION FOR THE PROPHYLAXIS OR TREATMENT OF CARDIOVASCULAR, CARDIOPULMONARY, PULMONARY OR RENAL DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190277-A1 | PHARMACEUTICAL COMBINATION FOR THE PREVENTION OR TREATMENT OF CARDIOVASCULAR, CARDIOPULMONARY, PULMONARY OR RENAL DISEASES | REN, ACE, TTR | PPARG 383/4885AGTR1 12/4885AGTR2 15/4885 |
| US-20090023932-A1 | Process for the Preparation of Telmisartan | ACE, ACE2, AGT | PPARG 1555/4885AGTR1 5/4885AGTR2 6/4885 |
| US-20050004193-A1 | Pharmaceutical combination for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary, or renal diseases | REN, ACE, TTR | PPARG 264/4885AGTR1 11/4885AGTR2 13/4885 |
| US-20060264491-A1 | Telmisartan production process | AGT, REN, ACE | PPARG 2049/4885AGTR1 4/4885AGTR2 5/4885 |
| US-20040259925-A1 | Pharmaceutical compositions and methds for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases | REN, AGTR2, ACE2 | PPARG 926/4885AGTR1 4/4885AGTR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.